Bayer – Group report and key figures
A report presented through summary slides of group's operations
Detailed history of financial performances between 2020 and 2024
An overview of the group's major business strategies
A medium-term outlook for opportunities and threats
650 €
WHAT IS THE GROUPS' FINANCIAL SITUATION ?
The financial indicators presented in this report include: consolidated revenue, consolidated EBIT and EBIT ratio, consolidated net profit and net profit rate, R&D expenditure and ratio, sales by segment and by region, profitability, liquidity and solvency ratios, free cash flow and capital expenditure.
WHAT ARE THE GROUP'S STRATEGIC PRIORITIES ?
Accelerate pharmaceutical pipeline transition
Mitigate legal risks while transitioning Crop Science portfolio
Restructure operations via Dynamic Shared Ownership
WHAT ARE THE GROUP'S STRENGTHS AND WEAKNESSES ?
Through a SWOT analysis, this report also provides an overview of the group's strengths (deep production capabilities and customer networks, etc.) and weaknesses (persistent legal overhang related to glyphosate litigation, with €5.7bn in provisions as of 2024, etc.).
Exploit the entire Xerfi content library (1,000 studies, 10,000 videos, and hundreds of articles) to produce market research, competitive intelligence, and strategic insights using simple prompts.
Detailed plan
Presentation
Segments
SWOT
Related reports
ACCESS THE REPORT
